Yael Baratz, Senior Partner and Chair of the Corporate & Licensing Group, and Elina Pevzner Kheshin, Senior Associate, represented a new incubator company formed at FutuRx incubator, by the name of A2i Therapeutics. Our team handled the formation of the company and the negotiation and drafting of the Collaboration Agreement with Atomwise of California, for the development of novel small molecule immune-oncology agents with the use of Atomwise’s proprietary AI platform. See article here: https://finance.yahoo.com/news/atomwise-futurx-launch-a2i-therapeutics-110000704.html?guccounter=1